The global bird flu treatment market size is estimated to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing outbreaks of avian influenza in the poultry industry and rising awareness about diagnosis among infected patients globally.
Avian influenza is a virus that causes bird flu. It causes sickness in birds, which have the potential to evolve and transmit to people. Depending on the protein found on the virus's surface, bird flu is referred to as H or N. The influenza A, B, and C viruses are the three varieties of influenza viruses. Influenza virus A is classified on the basis of surface proteins hemagglutinin (HA) and neuraminidase. The influenza A virus is further segmented into three categories based on its origin such as avian influenza, swine influenza, and other animal influenza viruses. People are infected with avian influenza through direct contact with contaminated birds. However, avian influenza is a rare disease in humans, it can occur when humans come into close contact with infected birds. A (H5N1) and A (H7N9) are two prevalent viruses that can cause serious illness in humans. Furthermore, the A (H7N9) virus subtype is extremely rare with a low pathogenicity and only found in East Asia. Europe and Africa have had a tremendous impact on many countries, which has resulted in tons of poultry infection and hundreds of human cases of serious disease across geographies.
The COVID-19 pandemic outbreak was an unprecedented global public health crisis that had impacted various industries and its long-term repercussions have had adverse impact on the bird flu treatment market. Furthermore, hospitals and healthcare services were drastically curtailed owing to social distancing measures enacted by governments around the world. Furthermore, the pandemic had a significant impact on the functioning of general hospital treatment for non-COVID-19 patients in hospitals globally.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing precautionary measures especially in the poultry industry to prevent the spread of bird flu is one of the key factors fueling the market growth.
- Ongoing R&D activities and rising investment by key players to develop improved products with better safety and efficacy are propelling the market growth.
- Several initiatives undertaken by government bodies in order to increase awareness about disorders among people are offering good opportunities to fuel the growth of the market in the near future.
- Unhealthy competition among the key players to secure larger market share is expected to hamper the market growth caused by price erosion.
- Focusing on regenerative drugs and the preference for combination therapy are expected to provide great opportunity for the market growth in the coming years.
Scope of the Report
The report on the global bird flu treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Bird Flu Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Types (Immunoglobulin, Ribavirin, Antivirals, Steroids, Prophylactic Antibiotics, Combination Treatment, and Others) and End-users (Institutional Health Centers, Hospitals, and Clinics)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
AbbVie Inc.; Abbott Laboratories; Alltech, Inc.; BioCryst Pharmaceuticals, Inc.; Aurobindo Pharma Ltd.; Cipla Ltd.; Bristol-Myers Squibb Co.; Chewy, Inc.; Dr. Reddy’s Laboratories Ltd.; F. Hoffmann-La Roche AG; Forest Pharmaceuticals, Inc.; GlaxoSmithKline PLC.; Gilead Sciences Inc.; Johnson & Johnson Services, Inc.; Merck & Co.; Macleods Pharmaceuticals Ltd.; Novartis International AG; Sinovac Biotech Ltd.; Pfizer Inc.; and Sanofi S.A.
Market Segment Insights
Antivirals segment is expected to grow at a rapid pace
Based on types, the global bird flu treatment market is segregated into immunoglobulin, ribavirin, antivirals, steroids, prophylactic antibiotics, combination treatment, and others. Antivirals segment is expected to grow at a rapid pace during the forecast period due to high prevalence of viral infections related to bird flu and rising demand for antiviral treatment drugs.
Hospital segment is projected to expand at a considerable CAGR
On the basis of end-users, the market is segmented into institutional health centers, hospitals, and clinics. The hospital segment is projected to expand at a considerable CAGR during the forecast period owing to the rise in adopting of POC tests in the hospital diagnosis of infection and examine disease progression based on symptoms or other parameters.
On the other hand, the clinic segment is expected to grow at a considerable rate in the market during the forecast period as it is cost-effective and easy products available in the market. This clinical diagnosis and treatment is a key method that can help medical workers to take decision quickly and address the problems more accurately.
North America is anticipated to constitute a key market share
In terms of regions, the global bird flu treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the projected period attributed to the encouraging reimbursement policies and increasing awareness about diseases transmitted from birds. In addition, the presence of major players such as Pfizer and Alcon in the region is expected to further promote the regional market growth.
On the other hand, the market of Asia Pacific is expected to represent a substantial market share in the coming years. The growth of the region attributed to the increasing investment in drugs development and growing number of clinical studies to evaluate the various alternative treatment procedures in the region.
Segments Covered in the Report
The global bird flu treatment market has been segmented on the basis of
- Prophylactic Antibiotics
- Combination Treatment
- Institutional Health Centers
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- AbbVie Inc.
- Abbott Laboratories
- Alltech, Inc.
- BioCryst Pharmaceuticals, Inc.
- Aurobindo Pharma Ltd.
- Cipla Ltd.
- Bristol-Myers Squibb Co.
- Chewy, Inc.
- Dr. Reddy’s Laboratories Ltd.
- F. Hoffmann-La Roche AG
- Forest Pharmaceuticals, Inc.
- GlaxoSmithKline PLC.
- Gilead Sciences Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co.
- Macleods Pharmaceuticals Ltd.
- Novartis International AG
- Sinovac Biotech Ltd.
- Pfizer Inc.
- Sanofi S.A.
Some of the major players competing in the market are AbbVie Inc.; Abbott Laboratories; Alltech, Inc.; BioCryst Pharmaceuticals, Inc.; Aurobindo Pharma Ltd.; Cipla Ltd.; Bristol-Myers Squibb Co.; Chewy, Inc.; Dr. Reddy’s Laboratories Ltd.; F. Hoffmann-La Roche AG; Forest Pharmaceuticals, Inc.; GlaxoSmithKline PLC.; Gilead Sciences Inc.; Johnson & Johnson Services, Inc.; Merck & Co.; Macleods Pharmaceuticals Ltd.; Novartis International AG; Sinovac Biotech Ltd.; Pfizer Inc.; and Sanofi S.A. These major players are implementing various marketing strategies such as capital investments, merger & acquisitions, and new product development to enhance their market position in the regional as well as global competition.